A Multicenter, Prospective, Non-interventional Study to Evaluate Effectiveness and Safety of Edoxaban in Patients 80 Years of Age or Older With Nonvalvular Atrial Fibrillation
Latest Information Update: 20 Sep 2024
At a glance
- Drugs Edoxaban (Primary)
- Indications Atrial fibrillation
- Focus Therapeutic Use
- Acronyms SILVERCARE_AF
- Sponsors Daiichi Sankyo Inc
- 13 Sep 2024 Status changed from recruiting to active, no longer recruiting.
- 12 Apr 2023 New trial record